It’s time to consider purchasing Zimmer Biomet Holdings, Inc.

Let’s talk about the popular Zimmer Biomet Holdings, Inc. The company’s shares have seen significant share price movement over the past few months on the NYSE, rising to highs of $116 and falling to lows of $102. Some price movements of shares can give investors a better opportunity to get into the stock and potentially buy at a lower price. One question to be answered is whether Zimmer Biomet Holdings’ current trading price of $104 reflects the true value of the large cap? Or is it currently undervalued, giving us the opportunity to buy? Let’s take a look at Zimmer Biomet Holdings’s outlook and value based on the latest financial data to see if there are any catalysts for a price change.

Check out our latest analysis for Zimmer Biomet Holdings

What is the opportunity at Zimmer Biomet Holdings?

Great news for investors – Zimmer Biomet Holdings is still trading at a fairly cheap price according to our price multiples model, where we compare the company’s price-to-earnings ratio to the industry average. We use the price-to-earnings ratio in this case because there is not enough visibility to predict its cash flows. The stock’s ratio of 21.14x is currently well below the industry average of 37.05x, meaning it is trading at a cheaper price relative to its peers. Although there may be another chance to buy again in the future. This is because Zimmer Biomet Holdings’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company’s shares will likely fall more than the rest of the market, providing an excellent buying opportunity.

Can we expect growth from Zimmer Biomet Holdings?

Investors looking for growth in their portfolio may want to consider a company’s prospects before purchasing its shares. While value investors argue that it is the intrinsic value relative to the price that matters most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow 33% over the next few years, the future looks bright for Zimmer Biomet Holdings. It appears that higher cash flow is forecast for the stock, which should contribute to a higher share valuation.

What does this mean for you

Are you a shareholder? Since ZBH is currently below the industry PE ratio, it could be a great time to increase your stock holdings. With a positive outlook on the horizon, it appears that this growth has not yet been fully taken into account in the share price. However, there are also other factors, such as financial health, to consider, which could explain the current price multiple.

Are you a potential investor? If you’ve had your eye on ZBH for a while, now might be the time to make the leap. Its dynamic future earnings outlook is not yet fully reflected in the current share price, which means it’s not too late to buy ZBH. But before making any investment decision, consider other factors, such as the track record of your management team, to make a well-informed investment decision.

If you want to know more about Zimmer Biomet Holdings as a company, it’s important to be aware of the risks it faces. For example, we discovered 2 warning signs which you should take a look at to get a better view of Zimmer Biomet Holdings.

If you are no longer interested in Zimmer Biomet Holdings, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Do you have feedback on this article? Worried about the content? Get in touch with us directly. Alternatively, email the editorial team (at) Simplywallst.com.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to bring you long-term focused analysis driven by fundamental data. Please note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St has no position in any of the stocks mentioned.